Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.
Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.
“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.
Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.
These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.
Considering buying AXSM stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。